Denali Therapeutics Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Denali is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases; it had no approved products and generated no product sales. All reported revenue was collaboration revenue. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Collaboration revenue | $5.8 million | $4.2 million | $9.5 million | $8.4 million |
| Research and development expense | $53.2 million | $51.9 million | $104.2 million | $89.3 million |
| General and administrative expense | $14.0 million | $15.1 million | $26.5 million | $24.4 million |
| Operating loss | $61.3 million | $62.8 million | $121.2 million | $105.3 million |
| Net loss | $58.8 million | $58.3 million | $115.5 million | $97.3 million |
| Net loss per share, diluted | $0.56 | $0.61 | $1.11 | $1.02 |
| Net cash used in operating activities | Not presented quarterly | Not presented quarterly | $97.8 million | $73.5 million |
At June 30, 2020, cash and cash equivalents were $137.2 million and marketable securities totaled $419.6 million, or $556.8 million combined. Total current assets were $559.4 million versus current liabilities of $58.5 million. Stockholders’ equity was $502.2 million; accumulated deficit was $541.1 million. The balance sheet reports no borrowings or other financial debt; it does report operating lease liabilities of $70.9 million. The company stated that available cash, cash equivalents and marketable securities were expected to fund projected operations for at least 12 months from the filing date, subject to assumptions.
Six-month investing cash outflow was $43.7 million, primarily reflecting net purchases of marketable securities and $1.2 million of property and equipment. Financing cash inflow was $199.3 million, including $193.9 million net proceeds from the January follow-on offering. The filing gives no meaningful product gross-margin measure; collaboration revenue remained far below operating expenses.
Material changes versus prior periods
- Six-month collaboration revenue rose 12% to $9.5 million, mainly from greater Takeda program activity; Sanofi retained-activities revenue declined as those activities wound down and transferred to Sanofi.
- Six-month R&D expense increased 17% to $104.2 million, chiefly from higher headcount, salaries and stock-based compensation, as well as increased costs for clinical-stage programs. Total operating expenses rose 15%.
- Six-month net loss increased 19% to $115.5 million. Q2 net loss was broadly flat year over year, while loss per share improved to $0.56 from $0.61, reflecting a larger weighted-average share count.
- Cash, cash equivalents and marketable securities increased from $455.2 million at December 31, 2019 to $556.8 million at June 30, 2020, supported in part by the January equity offering.
Outlook, developments and risks
- Management expected significant losses and expenses to continue, with R&D spending expected to increase over the next several years. The filing provides no formal earnings or revenue guidance.
- In June, Denali and Sanofi paused clinical work on RIPK1 candidate DNL747 after preclinical chronic-toxicity findings raised concern about dose escalation. They shifted focus toward backup candidate DNL788. Sanofi’s peripheral candidate DNL758 began a Phase 1b study in hospitalized patients with severe COVID-19 lung disease in July.
- COVID-19 had paused recruitment in several trials and an observational study; recruitment had resumed by the filing date. The company warned that further delays could affect clinical timelines, service providers, manufacturing, financing and program costs. It reported sufficient drug supply for ongoing trials and planned studies into 2021.
- On August 5, 2020, after quarter-end, Denali entered a binding provisional agreement with Biogen covering LRRK2 inhibitors and options on two transport-vehicle programs. Terms included a $560 million collaboration upfront payment, potential LRRK2 milestones exceeding $1.1 billion, and a separate $465 million equity investment for approximately 13.3 million new shares at $34.94 each. Closing remained subject to antitrust and other conditions and execution of a definitive collaboration agreement; these proceeds were not part of June 30 liquidity.
- Other significant commitments include up to $447 million of contingent F-star milestone payments and Lonza manufacturing commitments, including $18.0 million of open non-cancellable purchase orders and $12.1 million of total non-cancellable commitments as of June 30, 2020. Management reported no material pending litigation.
- Key risks include clinical and regulatory failure, early-stage pipeline uncertainty, reliance on collaborators and third-party manufacturers, intellectual-property protection, ongoing funding needs and pandemic-related disruption. Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the Biogen provisional agreement closes on the disclosed terms, including the upfront payment, equity issuance, cost sharing and program options.
- Clinical progress and safety data for DNL151, DNL343 and DNL310, and the development path for DNL788 following the DNL747 pause.
- Cash burn, collaboration revenue recognition and remaining contract liabilities, particularly as Takeda and Sanofi program activities change.
- Potential effects of COVID-19 on enrollment, trial timelines, third-party services and manufacturing supply.
- Future dilution and obligations associated with equity compensation, collaboration cost sharing, lease payments and contingent milestone commitments.